ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Jules Adam contributed 32 entries already.
Dutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with the European Investment Bank (EIB) participating through Angelini’s Aurea co-investment vehicle.
Agomab Therapeutics’ inhaled idiopathic pulmonary fibrosis (IPF) drug AGMB-447 showed lung-restricted exposure and inhibited its intended target in its first patient trial. The company plans to move the ALK5 inhibitor into phase 2 before the end of the year.
Two B7-H3-targeted antibody-drug conjugates licensed from Chinese biotechs have now delivered positive phase 3 survival data in relapsed small-cell lung cancer, strengthening the oncology bets GSK and Roche made in China.
Danish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the peptide into phase 2 testing in 2027.
French biotech Osivax and South Korea-based GC Biopharma have partnered to develop a seasonal influenza vaccine combining Osivax’s broad-spectrum OVX836 candidate with GC Biopharma’s marketed GC FLU vaccine.
For decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and cell therapies reshape the field, epilepsy is being redefined as many diseases with deeper biological roots.
Genmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement in progression-free survival (PFS) compared with R-GemOx.
Thalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten and transforming the company from a preclinical platform into a clinical-stage RNA therapeutics company.
Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.
Swedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under the terms of the deal, Alzecure will receive $10 million upfront and could receive more than $1 billion in development and commercial milestone payments, in addition to tiered royalties on future sales.